10.1186/1476-9255-3-1 [DOI] [PMC free article] [PubMed] [Google Scholar] 17.Grimm T, Schfer A, Hgger P
Foundayo may also improve heart health Narula also noted that Eli Lilly claims Foundayo has been shown to improve heart health indicators in research studies, such as waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure
Canadian researchers report average body composition changes of 15-25 pounds of fat loss combined with 8-15 pounds of lean mass gain over 12-16 week protocols
Clinical data shows dose escalation speed and individual receptor sensitivity influence side effect burden more than the drug itself
Fatigue: A significant drop in calorie intake can lead to tiredness as the body adapts to using fat stores for fuel
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025